MA42711A1 - Methods of treating disease states associated with masp-2-dependent complement activation - Google Patents

Methods of treating disease states associated with masp-2-dependent complement activation

Info

Publication number
MA42711A1
MA42711A1 MA42711A MA42711A MA42711A1 MA 42711 A1 MA42711 A1 MA 42711A1 MA 42711 A MA42711 A MA 42711A MA 42711 A MA42711 A MA 42711A MA 42711 A1 MA42711 A1 MA 42711A1
Authority
MA
Morocco
Prior art keywords
masp
methods
dependent complement
disease states
complement activation
Prior art date
Application number
MA42711A
Other languages
French (fr)
Other versions
MA42711B1 (en
Inventor
Gregory Demopulos
Thomas Dudler
Hans-Wilhelm Schwaeble
Original Assignee
Omeros Corp
Univ Leicester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corp, Univ Leicester filed Critical Omeros Corp
Priority claimed from PCT/US2016/061113 external-priority patent/WO2017083371A1/en
Publication of MA42711A1 publication Critical patent/MA42711A1/en
Publication of MA42711B1 publication Critical patent/MA42711B1/en

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Selon un aspect, l'invention concerne des méthodes d'inhibition des effets de l'activation du complément dépendant de masp-2 chez un sujet humain souffrant de tma associée à une greffe de cellules souches hématopoïétiques. Les méthodes comprennent l'étape d'administration, à un sujet qui en a besoin, d'une quantité d'un agent inhibiteur de masp-2 efficace pour inhiber l'activation du complément dépendant de masp-2.In one aspect, the invention relates to methods of inhibiting the effects of activation of masp-2 dependent complement in a human subject with tma associated with hematopoietic stem cell transplantation. The methods include the step of administering, to a subject in need thereof, an amount of a masp-2 inhibitory agent effective to inhibit activation of masp-2 dependent complement.

MA42711A 2015-11-09 2016-11-09 Methods of treating pathological conditions associated with activation of masp-2-dependent complement MA42711B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562252814P 2015-11-09 2015-11-09
PCT/US2016/061113 WO2017083371A1 (en) 2015-11-09 2016-11-09 Methods for treating conditions associated with masp-2 dependent complement activation

Publications (2)

Publication Number Publication Date
MA42711A1 true MA42711A1 (en) 2019-08-30
MA42711B1 MA42711B1 (en) 2020-12-31

Family

ID=68425990

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42711A MA42711B1 (en) 2015-11-09 2016-11-09 Methods of treating pathological conditions associated with activation of masp-2-dependent complement

Country Status (1)

Country Link
MA (1) MA42711B1 (en)

Also Published As

Publication number Publication date
MA42711B1 (en) 2020-12-31

Similar Documents

Publication Publication Date Title
PH12018501009A1 (en) Methods for treating conditions associated with masp-2 dependent complement activation
MA43131B1 (en) Compositions and methods of inhibiting arginase activity
MA41013A (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
SA519400950B1 (en) Compositions and Methods of Inhibiting MASP-3 for The Treatment of Various Diseases and Disorders
MX2016012123A (en) Compositions for modulating ataxin 2 expression.
UY36014A (en) ? DERIVED FROM PIRAZOL AMIDA, PHARMACEUTICAL COMPOSITION AND METHOD TO TREAT OR PREVENT AUTOIMMUNE, INFLAMMATORY, METABOLIC OR CANCEROSE DISEASES ?.
GEP20237541B (en) Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant
MX2022001778A (en) Methods of treating schizophrenia.
EA201692204A1 (en) COMPOSITIONS AND METHODS OF MODULATING THE EXPRESSION OF COMPLEX B FACTOR
MX2020003868A (en) Heterocyclic compound as a protein kinase inhibitor.
MX2018012902A (en) Compositions and methods for the treatment of lysosomal storage disorders and disorders characterized by lysosomal dysfunction.
ECSP21053104A (en) HSD17B13 EXPRESSION MODULATORS
PH12019502174A1 (en) Modulators of pcsk9 expression
EA202092748A1 (en) APOL1 EXPRESSION MODULATORS
MX2017012610A (en) Compositions and methods for inhibiting expression of the lect2 gene.
MX2018005352A (en) Methods and compositions for the treatment of amyloidosis.
MA54382A (en) USE OF COCCULUS HIRSUTUS EXTRACT FOR THE TREATMENT OF DENGUE FUE
MA42711A1 (en) Methods of treating disease states associated with masp-2-dependent complement activation
MX2018006631A (en) Compound for use in the prevention and treatment of neurodegenerative diseases.
FR3038605B1 (en) VICINAL PRIMARY DIAMINS ASSOCIATED WITH CHELATING MOTIFS OF METALS AND / OR FREE RADICALS, ACTIVE AGAINST CARBONYL AND OXIDIZING STRESSES AND THEIR USE
EA201990393A1 (en) COMPOSITIONS AND METHODS FOR INHIBITING MASP-3 USED FOR TREATING VARIOUS DISEASES AND DISORDERS
EA201991517A1 (en) COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY
EA202191138A1 (en) COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY